Personalis, Inc. (PSNL) News
Filter PSNL News Items
PSNL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PSNL News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PSNL News From Around the Web
Below are the latest news stories about PERSONALIS INC that investors may wish to consider to help them evaluate PSNL as an investment opportunity.
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 RevenueFREMONT, Calif., January 07, 2025--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance. |
The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159%The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company... |
Personalis price target raised to $8 from $7 at BTIGBTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares. The company’s $50M investment from Merck (MRK) strengthens its balance sheet with another strategic partner and represents a major derisking event, the analyst tells investors in a research note. The firm also cites Personalis having extended their contract with Moderna (MRNA), which is now a 10-year contact and has two 5-year renewable options, adding that despite the higher move in the |
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with ModernaFREMONT, Calif., December 19, 2024--Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen |
Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for BiopharmaWe recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other AI stocks. There is a growing concern in Silicon Valley that the progress around artificial intelligence is slowly “losing […] |
Personalis and Tempus Expand Collaboration to BiopharmaFREMONT, Calif., December 16, 2024--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD p |
Personalis to Participate at Upcoming Investor ConferencesFREMONT, Calif., November 20, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following investor conferences: |
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, Personalis ( NASDAQ:PSNL... |
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsPersonalis ( NASDAQ:PSNL ) Third Quarter 2024 Results Key Financial Results Revenue: US$25.7m (up 41% from 3Q 2023... |
Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ...Personalis Inc (PSNL) reports a 41% revenue increase and significant BioPharma growth, while navigating challenges in reimbursement and key partnerships. |